Publications by authors named "L Mileshkin"
The use of circulating tumour DNA (ctDNA) to profile mutational signatures represents a non-invasive opportunity for understanding cancer mutational processes. Here we present MisMatchFinder, a liquid biopsy approach for mutational signature detection using low-coverage whole-genome sequencing of ctDNA. Through analysis of 375 plasma samples across 9 cancers, we demonstrate that MisMatchFinder accurately infers single-base and doublet-base substitutions, as well as insertions and deletions to enhance the detection of ctDNA and clinically relevant mutational signatures.
View Article and Find Full Text PDFBackground: Chemo-immunotherapy is standard of care for women with recurrent or advanced mismatch repair deficient endometrial carcinoma. However, it is uncertain whether patients with mismatch repair deficient advanced or recurrent endometrial carcinoma derive less benefit from chemotherapy than those with mismatch repair proficient endometrial carcinoma.
Methods: We performed a meta-analysis of randomized controlled trials (RCTs) in advanced or recurrent endometrial carcinoma to determine the difference in the benefit of chemotherapy in mismatch repair deficient vs mismatch repair proficient endometrial carcinoma.
Article Synopsis
- Recent research on the HER2-targeted therapy trastuzumab-deruxtecan has led to a study examining HER2-low status in over 800 advanced endometrial cancer (EC) cases, which typically have a poor prognosis despite numerous treatment options.
- The study found that 17.2% of tumors were HER2-low, with higher frequencies in recurrent or metastatic EC (35.6%) and primary stage IV EC (29.9%), indicating HER2 status is present across various EC classifications without independent prognostic value.
- The findings suggest that a significant portion of high-risk and metastatic EC cases exhibit HER2 overexpression, emphasizing the importance of broad HER2 testing and potential treatment opportunities for diverse patient groups.
Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic tumors for which standardized diagnostic work-up fails to identify the primary site. We aimed to describe the Peter MacCallum Cancer Centre experience with F-FDG PET/CT in extracervical CUP with respect to detection of a primary site and its impact on management. A secondary aim was to compare overall survival (OS) in patients with and without a detected primary site.
View Article and Find Full Text PDFArticle Synopsis
- The GCIG Endometrial Cancer Consensus Conference was held in Incheon, South Korea, aimed at creating consensus statements to improve future clinical trials in endometrial cancer.
- Representatives from 33 member groups developed 18 statements across four key topics, focusing on treatment strategies and trial methodologies, including consideration for low-resource settings.
- For the first time, the conference included patient advocates and early-career investigators, resulting in a high consensus rate on the statements, reinforcing progress in global clinical research for endometrial cancer.